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establishing diagnostic mechanisms that enable rapid testing of these 
hypotheses in the clinic. This dual approach may provide a framework 
for a new clinical science that is driven by the knowledge of the mo-
lecular biology of individual tumors rather than by empirical determi-
nants of drug response. 
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Background: Epidermal growth factor receptor (EGFR) is a thera-
peutic target in non-small cell lung cancer (NSCLC) and head and 
neck squamous cell carcinoma (HNSCC). Patients with NSCLC with 
activating mutations in EGFR often have signiﬁcant tumor regressions 
with geﬁtinib treatment. In addition, approximately 30% of patients 
treated with geﬁtinib develop stable disease implicating additional 
mechanisms of geﬁtinib sensitivity. The majority of such patients do 
not harbor EGFR mutations and EGFR mutations in HNSCC are rare. 
As EGFR can be activated by one of its ligands (amphiregulin, EGF, 
TGF-alpha), we examined the relationship of EGFR ligands to the ef-
ﬁcacy of geﬁtinib and cetuximab using in vitro growth assays of EGFR 
wild type NSCLC and HNSCC cell lines. 
Methods: Amphiregulin, EGF and TGF-alpha in cell culture media 
was analyzed with ELISA assays in 18 cell lines, 14 NSCLC and 4 
HNSCC cell lines. This included four NSCLC with EGFR mutation. 
The remaining 14 cell lines were wild type for EGFR. All had wild type 
KRAS except for H358. The in vitro sensitivity was analyzed using 
MTS assay. EGFR, HER3, Akt, ERK1/2, Cyclin D1 and phosphoryla-
tion of these proteins were analyzed with Western blotting. Cell cycle 
was analyzed by ﬂow cytometry.
Result: TGF-alpha (range, 0 to 4.8pg/ml) was only detected in Calu3 
(116.6pg/ml) and H1666 (4.8pg/ml) cells. EGF (range, 0 to 2.2pg/ml) 
was detected at negligible level and did not vary signiﬁcantly. The pres-
ence of amphiregulin varied signiﬁcantly among the cell lines (range, 
4.6 to 1625.8pg/ml). All EGFR mutant cell lines had negligible levels 
of amphiregulin (<50.3pg/ml). Seven cell lines of the 14 cell lines 
with wild-type EGFR had > 250 pg/ml (range, 718.4 to 1625.8pg/ml) 
of amphiregulin detectable in media and all were sensitive to geﬁtinib 
with an IC50 of < 1 uM (range, 0.10 to 0.33). In addition, they were 
also sensitive to cetuximab (mean growth inhibition following10ug/ml 
cetuximab 56.8% (range, 33.1 to 87.1 %)) while those producing < 250 
pg/ml were resistant (mean growth inhibition following 10ug/ml cetux-
imab 0.95% (range -4.4 to 15.3%). Cell lines producing < 250 pg/ml 
of amphiregulin were also resistant to geﬁtinib in vitro (IC > 1 uM) In 
addition 6/7 sensitive cell lines expressed p-ERBB3 in contrast to 1/7 
resistant cell lines. The amphiregulin producing cell lines underwent 
G1/S arrest following either geﬁtinib or cetuximab treatment. Fur-
thermore, amphiregulin neutralizing antibodies inhibited growth of 3 
amphiregulin producing cell lines but not HN28, which did not produce 
amphiregulin. Amphiregulin producing sensitive cell lines exhibited 
dose dependent decrease in p-EGFR, p-ERBB3, p-Akt, p-ERK 1/2 and 
cyclin D1 following geﬁtinib. Cetuximab led to a dose dependent de-
crease in p-EGFR, p-ERK 1/2 and cyclin D1. Geﬁtinib and cetuximab 
had no effect on these proteins in cells without amphiregulin.
Conclusion: Our ﬁndings suggest that in EGFR wild type NSCLC and 
HNSCC cell lines the presence of an amphiregulin autocrine loop is a 
major determinant of in vitro sensitivity to geﬁtinib and cetuximab. In 
addition to EGFR mutations, amphiregulin expression may be suitable 
biomarker to select patients likely to beneﬁt from geﬁtinib treatment. 
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Background: Few details are known about the smoking history of 
patients developing lung cancer, especially so for users of hand rolled 
cigarettes. Norway appears to be the last Western country still using 
a signiﬁcant amount of roll tobacco, amounting to one third of total 
tobacco sales.
Methods: A prospective, questionnaire-based study on all persons de-
veloping primary lung cancer in Southern Norway between June 14th, 
2002 and June 13th, 2005.
Results: 83% of patients in an unselected population with newly 
diagnosed lung cancer had smoked primarily hand rolled cigarettes. 
The hand rolled cigarette smokers had consumed signiﬁcantly less 
pack-years of tobacco (32,3, SD19), and smoked fewer cigarettes per 
day (14,9 SD7), than those using fabricated cigarettes (40,0, SD26, 
and 19,8, SD10, p=0,023 and p<0,0001, respectively). The use of pack 
tobacco is much more frequent in this study than expected from ofﬁcial 
sales statistics. Smoking debut was 17,9 years (SD5). Mean age for 
developing lung cancer was 68 (SD11) years.
